Full Press Release Details
Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug
is being developed as an oral dosage form of a GLP1-analog aimed at improving
glycemic control in adults with type 2 diabetes
Israel - September 16, 2008 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB),
developer of oral drug delivery systems, announced today that it has launched
pre-clinical trials of ORMD 0901, a GLP1-analog. ORMD
belongs to the Incretin family of drugs which helps to manage diabetes,
including reduction in blood glucose levels and inhibiting glucagon secretion.
have been cited in causing regeneration of pancreatic insulin secreting cells,
and in tissue protective properties including protection of the heart. GLP1
analogs are associated with gradual weight loss, which is very desirable in
launch of pre-clinical trials of ORMD 0901 and expansion of Oramed's platform
marks the next strategic milestone for our company as we demonstrate the
effectiveness of our oral delivery technology in yet another important family
polypeptide drugs for diabetes, that are until now only available in injection
form," said Oramed CEO Nadav Kidron.
to conduct the ORMD 0901 trials at Hadassah University Medical Center and they
are expected to conclude by the end of 2008.
plans to launch phase 2b trials of ORMD 0801, its oral insulin capsule, in
in the first quarter of 2009.
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs presently delivered via injection. Oramed is seeking to
revolutionize the treatment of diabetes through its patented flagship product,
an orally ingestible insulin capsule currently in phase 2 clinical trials.
Established in 2006, Oramed's technology is based on over 25 years of research
by top research scientists at Jerusalem's Hadassah Medical Center. The Company's
corporate and R&D headquarters are based in Jerusalem.
more information, please visit www.oramed.com
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
obtaining regulatory approval for our product candidates; competition from
pharmaceutical or biotechnology companies; and the company's ability to obtain
additional funding required to conduct its research, development and
commercialization activities. Please refer to the company's filings with the
Securities and Exchange Commission for a comprehensive list of risk factors
could cause actual results, performance or achievements of the company to differ
materially from those expressed or implied in such forward looking statements.
The company undertakes no obligation to update or revise any forward-looking
and Investor Relation Contacts:
Finn Israel for Oramed